Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 531 clinical trials
Featured trial
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis

  • 208 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind Study comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

A Phase 3, Randomized, Double-Blind Study comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease

  • 308 views
  • 23 Nov, 2020
  • 1 location
Featured trial
  • 820 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 248 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy

This study will evaluate the safety and effectiveness of treating patients with severe aplastic anemia (SAA) or myelopdysplastic syndrome (MDS) with both peripheral blood stem cells from a family member and umbilical cord blood stem cells from an unrelated donor. Patients with SAA or MDS for whom other treatments have …

anemia
aplastic anemia
anemia studies
myelodysplastic syndromes
myelodysplastic syndrome (mds)
  • 54 views
  • 22 Dec, 2020
  • 1 location
Featured trial
Do you suffer from lower back pain?

Do you suffer from lower back pain?

  • 1590 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren’s syndrome

A multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren’s syndrome

  • 1420 views
  • 25 Mar, 2021
  • 1 location
RA-PRO PRAGMATIC TRIAL (RA-PROPR)

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing

prednisone
methotrexate
sulfasalazine
tocilizumab
abatacept
  • 0 views
  • 28 Jun, 2022
  • 1 location
Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.

rheumatism
prednisone
corticosteroids
DMARD
erythrocyte sedimentation
  • 0 views
  • 19 Sep, 2022
  • 8 locations
A Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

body mass index
rheumatism
DMARD
antirheumatics
biologic disease-modifying antirheumatic drug
  • 12 views
  • 19 Aug, 2022
  • 9 locations